Terpene Lactones

Compound Class	Terpene trilactones — cage-like diterpene (ginkgolides) and sesquiterpene (bilobalide) lactones; structurally unique to Ginkgo biloba
Representative Members	Ginkgolides A, B, C, and J (~2.8–3.4% of extract); bilobalide (~2.6–3.2%)
Botanical Sources	Ginkgo biloba — found in no other plant genus
Plant Part(s)	Leaf (and root bark)
Typical Standardisation	6% terpene lactones — the second half of the classic 24%/6% EGb 761 specification. Ginkgolic acids must be <5 ppm
Primary Applications	Cerebrovascular and microcirculatory formulation; platelet-activating-factor antagonism; neuroprotective positioning
Claim Strength (Overview)	Emerging — PAF antagonism is a well-defined mechanism; the clinical evidence is inseparable from the whole-extract literature
Buy from Herbuno	Ginkgo Biloba Extract 24%/6% Powder (Ginkgo) | Standardized Ginkgo biloba → Ginkgo Biloba Extract Powder →

Name origin: The ginkgolides are named directly for their source and were designated A, B, C, J, and M in order of isolation; bilobalide takes its name from the species epithet biloba, describing the leaf’s characteristic two-lobed form. Chemically these are terpene trilactones — molecules bearing three lactone rings arranged around a rigid cage-like carbon skeleton with a tert-butyl group, an architecture so structurally unusual that its total synthesis (achieved by Corey) is regarded as a landmark in organic chemistry. Traditional use: There is no traditional use of ginkgo terpene lactones as such, and it would be misleading to construct one. These molecules were unknown until 20th-century phytochemistry isolated them, and the leaf extract in which they are delivered is itself a modern European pharmaceutical development rather than an inherited preparation. What is genuinely ancient is the tree — a living fossil with no close living relatives — and its seeds, which have a Chinese culinary and medicinal record entirely separate from the leaf. Research trajectory: Terpene lactone research took a distinctive turn in the 1980s with the discovery that ginkgolide B is a potent and selective antagonist of platelet-activating factor (PAF), a phospholipid mediator central to inflammation, allergy, and thrombosis. This gave the fraction a precise, well-defined molecular mechanism that the flavonoid half of the extract lacks, and it remains the most rigorously characterized pharmacology in the entire ginkgo literature. Commercial source: Delivered as part of Ginkgo biloba leaf extract standardized to the 24%/6% specification; terpene lactones are not commercially available as a standalone standardized botanical ingredient at scale.

---

Evidence for Terpene Lactones Applications

The terpene lactones are the structurally distinctive half of the ginkgo extract, and the specification is precise. EGb 761 is adjusted to contain 22.0–27.0% ginkgo flavonoids calculated as flavone glycosides and 5.0–7.0% terpene lactones, the latter consisting of 2.8–3.4% ginkgolides A, B, and C together with 2.6–3.2% bilobalide, alongside 7% proanthocyanidins, low-molecular-weight organic acids, and less than 5 ppm ginkgolic acids — produced by acetone extraction at a drug-to-extract ratio of 35–67:1 (Defeudis 1999). Note the split: roughly half the terpene lactone fraction is ginkgolides and half is bilobalide, and these are chemically and pharmacologically different classes (diterpene versus sesquiterpene). Claim strength: High (specification fact).

An honest and important limitation is now acknowledged in the primary literature: although flavone glycosides and terpene lactones together account for approximately 30% of the extract and are recognized as active constituents, they do not fully explain the overall therapeutic effects of ginkgo extracts, with pharmacopoeial specifications defining only these two fractions and rendering the remaining 70% of the extract unspecified and variable in composition — a gap in which proanthocyanidins have recently attracted increasing scientific attention (Oxid Med Cell Longev 2013). This is a candid admission that the 24%/6% specification, for all its pharmaceutical rigour, leaves most of the extract uncharacterized. Claim strength: Moderate.

The best-defined pharmacology in the entire ginkgo literature belongs to ginkgolide B: it is a potent and selective antagonist at the platelet-activating factor (PAF) receptor. PAF is a phospholipid mediator driving platelet aggregation, inflammatory cascades, bronchoconstriction, and increased vascular permeability. Ginkgolide B’s antagonism of it provides a coherent mechanistic account of ginkgo’s reported effects on blood viscosity, microcirculation, and perfusion — and, notably, is also the mechanistic basis for ginkgo’s bleeding-risk caution, meaning the benefit and the risk arise from the same receptor interaction. Claim strength: Moderate (mechanistic).

Bilobalide is pharmacologically distinct from the ginkgolides and should not be lumped with them. As a sesquiterpene rather than a diterpene, it does not act principally through PAF antagonism; its documented activities centre on neuroprotection, mitochondrial protection, and modulation of GABAergic neurotransmission. Notably, in work examining EGb 761’s effects on prefrontal dopamine, bilobalide treatment was found to be without effect, while flavonol glycoside and ginkgolide fractions drove the increase — a useful reminder that "terpene lactones 6%" aggregates two constituent groups with materially different profiles. Claim strength: Emerging.

An honest scoping note that formulators should internalize: there is essentially no clinical evidence for terpene lactones in isolation. Every meaningful human trial has used the whole standardized extract, in which the terpene lactones are inseparable from the flavone glycosides, the proanthocyanidins, and the unspecified remainder. Consequently, the clinical picture for this fraction is the clinical picture for ginkgo extract overall — including the negative dementia-prevention findings documented on the companion Ginkgo Flavone Glycosides page in this index, which apply equally here. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries Ginkgo biloba leaf extract standardized to the 24%/6% specification, which delivers the terpene lactone fraction at the pharmaceutically defined 6% level alongside 24% flavone glycosides, plus unstandardized ginkgo leaf extract in powder, water-soluble, and oil-soluble formats. Terpene lactones are not practically available as a standalone standardized botanical ingredient, so the 24%/6% extract is the route to this fraction.

Because no clinical trial has tested terpene lactones in isolation, dosing guidance necessarily derives from whole-extract studies. Clinical dosing has clustered at 120–240 mg/day of standardized extract, with the systematic-review evidence indicating that symptomatic cognitive benefit was convincingly demonstrated only at 240 mg/day. At the 6% specification, a 240 mg daily dose delivers roughly 14 mg/day of total terpene lactones. Formulators should present dose in terms of the standardized extract rather than implying an independently validated terpene lactone dose.

Analytical verification should specify total terpene lactones by HPLC with the individual breakdown of ginkgolides A, B, C, and J and bilobalide reported separately — not merely the summed 6% figure — since ginkgolides and bilobalide have materially different pharmacology and the ginkgolide:bilobalide ratio is a real quality variable. Ginkgolic acid content below 5 ppm is a non-negotiable safety specification for any ginkgo material. Adulteration to inflate assays is a documented problem in this trade, making a full terpene lactone fingerprint a worthwhile verification rather than a formality.

The most important safety consideration for this fraction follows directly from its mechanism: ginkgolide B’s PAF-receptor antagonism inhibits platelet aggregation, and ginkgo has documented antiplatelet activity with case reports of bleeding events. Clear caution regarding concurrent use with anticoagulant or antiplatelet medication, and discontinuation before surgery, is warranted — and formulators should understand that this is not an incidental side effect but the same receptor interaction that underlies the ingredient’s circulatory positioning. Ginkgolic acids remain the separate allergenic and cytotoxic concern addressed by the <5 ppm limit.

---

Frequently Asked Questions — Terpene Lactones

What makes terpene lactones unique to ginkgo?
They are found in no other plant genus. The ginkgolides are cage-like diterpene trilactones with an unusual tert-butyl group, and bilobalide is a related sesquiterpene. Their structural architecture is so distinctive that the total synthesis of ginkgolide B is regarded as a landmark achievement in organic chemistry.

What is PAF antagonism?
Ginkgolide B is a potent, selective antagonist at the platelet-activating factor receptor. PAF is a phospholipid mediator driving platelet aggregation, inflammation, and vascular permeability. Blocking it explains ginkgo's reported effects on blood viscosity and microcirculation — and is also the mechanistic basis for its bleeding-risk caution, so benefit and risk arise from the same interaction.

Are ginkgolides and bilobalide the same thing?
No, and the "6% terpene lactones" figure aggregates them misleadingly. Ginkgolides are diterpenes acting mainly through PAF antagonism; bilobalide is a sesquiterpene whose activity centres on neuroprotection and GABAergic modulation. In one study of prefrontal dopamine, bilobalide had no effect while the ginkgolide fraction did.

Do the 24% and 6% fractions explain ginkgo's effects?
Not fully, and the literature now says so openly. Together they account for roughly 30% of the extract. Pharmacopoeial specifications define only these two fractions, leaving the remaining 70% unspecified and variable — a gap in which proanthocyanidins have recently drawn attention as possible additional contributors.

Related compounds: Ginkgo Flavone Glycosides, Ginkgolide B, Bilobalide, Quercetin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery